Why an M1 Antagonist Could Be a More Selective Model for Memory Impairment than Scopolamine.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. JAK4D, a first-in-class thyrotropin-releasing hormone analogue, reverses scopolamine-induced memory deficits.Brain communications · 2026
   Article
2. Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids.International journal of molecular sciences · 2022
   Review
3. Discovery of the First Selective MACS pharmacology & translational science · 2021
   Article
4. Comparison of the muscarinic antagonist effects of scopolamine and L-687,306.Behavioural pharmacology · 2020
   Article
5. Spatial Updating Depends on Gravity.Frontiers in neural circuits · 2020
   Article
6. No interaction between rivastigmine and citalopram on memory and novelty processing in healthy human volunteers.Journal of psychopharmacology (Oxford, England) · 2019
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as